Histamine induces Toll-like receptor 2 and 4 expression in endothelial cells and enhances sensitivity to Gram-positive and Gram-negative bacterial cell wall components

Immunology

Volumn 113, Issue 2, 2004, Pages 224-233

  Talreja, Jaya ^a   Kabir, Mohammad H ^a   Filla, Michael B ^a   Stechschulte, Daniel J ^a   Dileepan, Kottarappat N ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelial cells; Histamine; Interleukin 6; Toll like receptor 2; Toll like receptor 4

Indexed keywords

HISTAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; MESSENGER RNA; PEPTIDOGLYCAN; PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ARTICLE; BACTERIAL CELL WALL; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; INFLAMMATION; MAST CELL; PRIORITY JOURNAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, DIFFERENTIATION; ANTIGENS, SURFACE; BACTERIA; CELL WALL; CELLS, CULTURED; ENDOTHELIAL CELLS; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; MEMBRANE GLYCOPROTEINS; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; PEPTIDOGLYCAN; RECEPTORS, CELL SURFACE; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER; TEICHOIC ACIDS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; UP-REGULATION;

EID: 4744356684     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2004.01946.x     Document Type: Article

References (60)

1. Barnes PJ. Histamine receptors in the lung. Agents Action (Suppl.) 1991; 33:103-22.
2. Hill SJ. Multiple histamine receptors: properties and functional characteristics. Biochem Soc Trans 1992; 20:122-5.
3. Elenkov IJ, Webster E, Papanicolaou DA, Fleisher TA, Chrousos GP, Wilder RL. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J Immunol 1998; 161:2586-93.
4. Dileepan KN, Lorsbach RB, Stechschulte DJ. Mast cell granules inhibit macrophage-mediated lysis of mastocytoma cells (P815) and nitric oxide production. J Leukoc Biol 1993; 53:446-53.
5. Clark RA, Gallin JI, Kaplan AP. The selective chemotactic activity of histamine. J Exp Med 1975; 142:1462-76.
6. Dileepan KN, Simpson KM, Lynch SR, Stechschulte DJ. Dismutation of eosinophil superoxide by mast cell granule superoxide dismutase. Biochem Arch 1989; 5:153-60.
7. Ogden BE, Hill HR. Histamine regulates lymphocyte mitogenic responses through activation of specific H1 and H2 histamine receptors. Immunology 1980; 41:107-14.
8. Beer DJ, Matloff SM, Rocklin RE. The influence of histamine on immune and inflammatory responses. Adv Immunol 1984; 35:209-68.
9. Li Y, Chi Y, Stechschulte DJ, Dileepan KN. Histamine-induced production of IL-6 and IL-8 by human coronary artery endothelial cells is enhanced by endotoxin and TNF-α. Microvascular Res 2001; 61:253-62.
10. Kalsner S, Richards R. Coronary arteries of cardiac patients are hyper reactive and contain stores of amines: a mechanism for coronary spasm. Science 1984; 223:1435-7.
11. Sakata YK, Komamura K, Hirayama A, Nato S, Kitakaze M, Hori M, Kodama K. Elevation of the plasma histamine concentration in the coronary circulation in patients with variant angina. Am J Cardiol 1996; 77:1121-6.
12. Delneste Y, Lassalle P, Jeannin P. Histamine induces IL-6 production by human endothelial cells. Clin Exp Immunol 1994; 98:344-9.
13. Jeannin P, Delneste Y, Gossette P, Molet S, Lassalle P, Hamid Q, Tsicopoulos A, Tonnel AB. Histamine induces IL-8 secretion by endothelial cells. Blood 1994; 84:2229-33.
14. Hough LB. Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 2001; 59:415-9.
15. Walsh GM, Annunziato L, Frossard N et al. New insights into the second generation antihistamines. Drugs 2001; 61:207-36.
16. Kohka H, Nishibori M, Iwagaki H, et al. Histamine is a potent inducer of IL-18 and IFNγ in human peripheral blood mononuclear cells. J Immunol 2000; 164:6640-6.
17. Caron G, Delneste Y, Roelandts E, Duez C, Bonnefoy JY, Pestel J, Jeannin P. Histamine polarizes human dendritic cells into Th2 cell-promoting effector dendritic cells. J Immunol 2001; 167:3682-6.
18. Jutel M, Watanabe T, Klunker S et al. Histamine regulates T-cell and Ab responses by differential expression of H1 and H2 receptors. Nature (Lond) 2001; 413:420-4.
19. Leurs R, Blandina P, Tedford C, Timmerman H. Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol Sci 1998; 19:177-83.
20. Hough LB, Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhlen S, eds. Histamine, in Basic Neurochemistry: Molecular, Cellular and Medical Aspects. Philadelphia: Lippincott-Raven, 1999:293-313.
21. Nakamura T, Itadani H, Hidaka Y, Ohta M, Tanaka K. Molecular cloning and characterization of a new histamine receptor, HH4R. Biochem Biophys Res Commun 2000; 279:615-620.
22. Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 2000; 275:36781-6.
23. Morse KL, Behan J, Laz TM et al. Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther 2001; 296:1058-66.
24. Gantner F, Sakai K, Tusche MW, Cruikshank WW, Center DM, Bacon KB. Histamine (H4) and (H2) receptors control histamine-induced interleukin-16 release from human CD8(+) T cells. J Pharmacol Exp Ther 2002; 303:300-7.
25. Chi L, Bittel LS, Smirnova I, Stechschulte DJ, Dileepan KN. Signal transduction pathways in mast cell granule-mediated endothelial cell activation. Med Inflamm 2003; 12:79-87.
26. Grayston JT, Kuo CC, Campbell LA, Benditt EP. Chlamydia pneumoniae, strain TWAR and atherosclerosis. Eur Heart J 1993; 14:66-71.
27. Brown Z, Gerritsen ME, Carley WW, Strieter RM, Kunkel SL, Westwick J. Chemokine gene expression and secretion by cytokine activated human microvascular endothelial cells. Differential regulation of monocyte chemoattractant protein-1 and interleukin-8 in response to interferon-gamma. Am J Pathol 1994; 145:913-21.
28. Kawamura N, Imanishi N, Koike H, Nakahara H, Phillips L, Morooka S. Lipoteichoic acid-induced neutrophil adhesion via E-selectin to human umbilical vein endothelial cells (HUVECs). Boichem Biophys Res Commun 1995; 217:1208-15.
29. Blease K, Chen Y, Hellewell PG, Burke-Gaffney A. Lipoteichoic acid inhibits lipopolysaccharide-induced adhesion molecule expression and IL-8 release in human lung microvascular endothelial cells. J Immunol 1999; 163:6139-47.
30. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S. Toll-like receptor-4 deficient mice are hyporesponsive to lipopolysaccharide. Evidence for TLR-4 as the lps gene product. J Immunol 1999; 162:3749-52.
31. Nagai Y, Akashi S, Nagafuku M, et al. Essential role of MD-2 in LPS responsiveness and TLR-4 distribution. Nat Immunol 2002; 3:667-72.
32. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J Immunol 2000; 166:1938-89.
33. Lehner MD, Morath S, Michelsen KS, Schumann RR, Hartung T. Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators. J Immunol 2001; 166:5161-7.
34. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21:335-76.
35. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takeda H, Ogawa T, Takeda K, Akira S. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999; 11:443-51.
36. Kiechl S, Lorenz E, Reindl M, Weidermann C, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA. Toll-like receptor 4 polymorphism and atherogenesis. N Engl J Med 2002; 347:185-92.
37. Edfeldt K, Swedenberg J, Hansson GK, Yan CQ. Expression of Toll-like receptors in human atherosclerotic lesions. A possible pathway for plaque activation. Circulation 2002; 105:1158-61.
38. Kleijn DD, Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovasc Res 2003; 60:58-67.
39. Ito N, Li Y, Suzuki T, Stechschulte DJ, Dileepan KN. Transient degradation of NF-κB proteins in macrophages after interaction with mast cell granules. Med Inflamm 1998; 7:397-407.
40. Muroi M, Muroi Y, Yamamoto K, Suzuki T. Influence of 3′ half-site sequence of NF-κB motifs on the binding of lipopolysaccharide-activable macrophage NF-κB proteins. J Biol Chem 1993; 268:19534-9.
41. Miyake K. Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: unique roles for MD-2. Int Immunopharmacol 2003; 3:119-28.
42. Talreja J, Dileepan K, Filla M, Dileepan KN, Stechschulte DJ. Lipopolysaccharide unresponsiveness of human conjunctival epithelial cells (HCEC) is associated with the lack of MD2 expression. FASEB J 2003; 17:C57.
43. Janssens S, Beyaert E. A universal role for MyD88 in TLR/IL-IR-mediated signaling. Trends Biochem Sci 2002; 27:474-82.
44. Takeuchi O, Akira S. MyD88 as a bottle neck in Toll/IL-1 signaling. Curr Top Microbiol Immunol 2002; 270:155-67.
45. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406:782-7.
46. Krutzik SR, Sieling PA, Modlin RL. The role of Toll-like receptors in host defense against microbial infection. Curr Opin Immunol 2001; 13:104-8.
47. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-7.
48. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57B1/10ScCr mice. Mutations in Tlr4 gene. Science 1998; 282:2085-8.
49. Zeuke S, Ulmer AJ, Kusumoto S, Katus HA, Heine H. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc Res 2002; 56:126-34.
50. Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, Segal DM. Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol 2001; 166:249-55.
51. Forman MB, Oates JA, Robertson D, Robertson RM, Roberts LJ, Virmani R. Increased adventitial mast cells in a patient with coronary spasm. N Engl J Med 1985; 313:1138-41.
52. Jeziorska M, McCollum C, Wooley DE. Mast cell distribution, activation, and phenotype in atherosclerotic lesions of human carotid arteries. J Pathol 1997; 182:115-22.
53. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189:1777-82.
54. Kennedy MN, Mullen GED, Leifer CA, Lee CW, Mazzoni A, Dileepan KN, Segal DM. A complex of soluble MD2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4. J Biol Chem 2004; 279:34698-704.
55. Faure E, Thomas L, Xu H, Medvedev AE, Equils O, Arditi M. Bacterial lipopolysaccharide and IFNγ induce toll-like receptor 2 and toll-like receptor 4 expression in human endothelial cells: role of NF-kB activation. J Immunol 2001; 166:2018-24.
56. Faure E, Equils O, Sieling PA, et al. Bacterial lipopolysaccharide activates NF-κB through Toll-like receptor-4 in cultured human dermal endothelial cells. J Biol Chem 2000; 275:11058-63.
57. Liberman TA, Baltimore D. Activation of interleukin 6 gene expression through the NF-κB transcription factor. Mol Cell Biol 1990; 10:2327-34.
58. Shimazu H, Mitomo K, Watanabe T, Okamoto S, Yamamoto K. Involvement of NF-κB in the activation of IL-6 gene by inflammatory lymphokines. Mol Cell Biol 1990; 10:561-8.
59. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Ann Rev Immunol 1994; 12:141-50.
60. Baeuerle PA, Baltimore D. NF-κB: ten years after. Cell 1996; 87:13-20.